Skip to main content
. Author manuscript; available in PMC: 2013 Jul 30.
Published in final edited form as: Cancer Res. 2010 May 25;70(12):4949–4960. doi: 10.1158/0008-5472.CAN-09-1962

Fig. 5.

Fig. 5

A. Nuclear fractions of HL-60 cells tranfected with vector (pcDNA3) or pcDNA3-DRIP205 constructs were lysed and analyzed by western blot analysis. PCNA was used as a loading control for nuclear lysates. B, C. HL-60 cells tranfected with vector (pcDNA3) or pcDNA3-DRIP205 constructs were treated with 0.5 μ M CDDO for 120 hours, and induction of myelomonocytic differentiation was determined by CD11b flow cytometry (%CD11b(+) cells, (B)) or NBT assay (C). Data represent average results from three independent experiments. D. HL-60 cells tranfected with vector (pcDNA3) or pcDNA3-DRIP205 constructs were pretreated with 4 μ M T007, a PPARγ antagonist, for 1 hour, followed by 0.75 μ M CDDO for 120 hours. Data represent average results (mean±SD) of three independent experiments. Induction of differentiation was determined by CD11b flow cytometry. ** denotes p=0.01, and *p=0.02.